Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1211-MM,High Risk, RVD+/-ELO | 1 | T | 1 RVD/Elo Dose Level 1 | 110 | 8 | 0 | 0 | 0 | 0 | 0 | 02/13/2013 | 182 | 59 |
| 4 RVD | 68 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 5 RVD/Elo | 66 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 142 | 0 | 0 | 0 | 0 | 0 | |||||||||
| S1304-MM,relapsed/refractory, Car+Dex | 1 | N | 1 Dex+Low Dose Carfilzomib | 140 | 72 | 0 | 0 | 0 | 0 | 0 | 02/12/2014 | 5 | 2 | |
| 2 Dex+High Dose Carfilzomib | 71 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 143 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 2 | Y | 3 Dex+High Dose Carfilzomib | 140 | 22 | 0 | 0 | 0 | 0 | 0 | 02/12/2014 | ||||
| 22 | 0 | 0 | 0 | 0 | 0 | |||||||||
| S0777-MM, Len Dex +/- Bortezomib | 1 | N | 1 Lenalidomide/Dex | 484 | 261 | 0 | 0 | 0 | 0 | 0 | 07/28/2008 | 17 | 4 | |
| 2 Bortezomib/Lenalidomide/Dex | 264 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 525 | 0 | 0 | 0 | 0 | 0 | |||||||||
| Yes | E1A11-MM, frontline, BLD vs CLD | 1 | E | Total Registrations | 128 | 76 | 38 | 19 | 7 | 0 | 03/05/2014 | 299 | 129 | |
| 128 | 76 | 38 | 19 | 7 | 0 | |||||||||
| E3A06-AMM, Lenalidomide vs Observation | 0 | E | Total Registrations | 37 | 12 | 8 | 6 | 3 | 0 | 02/01/2011 | 272 | 125 | ||
| 37 | 12 | 8 | 6 | 3 | 0 | |||||||||
| 1 | E | Total Registrations | 35 | 5 | 2 | 2 | 1 | 1 | 02/01/2011 | |||||
| 35 | 5 | 2 | 2 | 1 | 1 | |||||||||
| No | A061402-Solitary Plasmacytoma, adj sys+Zol vs Zol | 0 | E | Total Registrations | 1 | 1 | 1 | 0 | 0 | 0 | 01/27/2017 | |||
| 1 | 1 | 1 | 0 | 0 | 0 | |||||||||
| E1A11-MM, frontline, BLD vs CLD | 0 | E | Total Registrations | 139 | 89 | 46 | 22 | 5 | 0 | 03/05/2014 | 299 | 129 | ||
| 139 | 89 | 46 | 22 | 5 | 0 | |||||||||
| 2 | E | Total Registrations | 30 | 18 | 13 | 5 | 1 | 0 | 03/05/2014 | |||||
| 30 | 18 | 13 | 5 | 1 | 0 | |||||||||